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Abstract
Heparan sulfate proteoglycans (HSPGs) play a key role in shaping the tumor microenvironment by presenting growth
factors, cytokines, and other soluble factors that are critical for host cell recruitment and activation, as well as promoting
tumor progression, metastasis, and survival. M402 is a rationally engineered, non-cytotoxic heparan sulfate (HS) mimetic,
designed to inhibit multiple factors implicated in tumor-host cell interactions, including VEGF, FGF2, SDF-1a, P-selectin, and
heparanase. A single s.c. dose of M402 effectively inhibited seeding of B16F10 murine melanoma cells to the lung in an
experimental metastasis model. Fluorescent-labeled M402 demonstrated selective accumulation in the primary tumor.
Immunohistological analyses of the primary tumor revealed a decrease in microvessel density in M402 treated animals,
suggesting anti-angiogenesis to be one of the mechanisms involved in-vivo. M402 treatment also normalized circulating
levels of myeloid derived suppressor cells in tumor bearing mice. Chronic administration of M402, alone or in combination
with cisplatin or docetaxel, inhibited spontaneous metastasis and prolonged survival in an orthotopic 4T1 murine mammary
carcinoma model. These data demonstrate that modulating HSPG biology represents a novel approach to target multiple
factors involved in tumor progression and metastasis.
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Introduction
Metastatic cancer is a complex disease comprised of multiple
microenvironments or niches involving the primary tumor, meta-
static lesions, and the bone marrow [1]. These niches are inter-
connected by circulating tumor- and host-derived cells as well as
soluble factors. Notably, many of the soluble factors implicated in
progression of metastatic disease are currently targets for anti-
cancer strategies. Tyrosine kinase inhibitors that inactivate path-
ways known to be important in certain cancers, such as chronic
myeloid leukemia, renal cancer, gastrointestinal stromal tumor,
have proven to have a profound effect on the clinical outcome,.
However, in practice, the beneficial activity of such agents can be
short-lived presumably due to mutations in the target or redun-
dant pathways exploited by multiple tumor types. For example,
anti-VEGF therapies, such as bevacizumab, can lead to tumors
adaptation by exploiting alternative angiogenic factors and recrui-
ting myeloid derived suppressor cells (MDSCs) to promote angio-
genesis [2], resulting in resistance to these therapies and potentially
the emergence of tumor cells with a more aggressive phenotype
[3,4]. To circumvent these shortcomings, there has been an in-
creased effort in identifying combinations of targeted drugs that
can be used together in cancer treatments. However, the combina-
tion of potent single-targeted drugs is often limited by their safety
profile, and can result in unexpected adverse activity [5]. Despite
these shortcomings, targeting extracellular, soluble factors has a
number of significant benefits, including ease of delivery, and the
ability to target multifaceted compartments, including the primary
tumor, circulating tumor cells, as well as metastatic loci [6].
In an effort to design such an agent, we have focused on a
unique class of molecules, the heparan sulfate proteoglycans
(HSPGs). HSPGs are highly charged linear polysaccharides cova-
lently bound to core proteins associated with the plasma mem-
brane, such as syndecans and glypicans, or the basement mem-
brane, such as perlecan, agrin, and collagen XVIII [7]. Many of
the soluble factors that support tumor progression are HSPG-
binding proteins [8–10] and this binding is known to modulate
activity [9,10]. For example, HSPG-bound growth factors, such
as VEGF, FGF2, and HGF support the growth of new blood
vessels. In addition, tumor cells utilize chemokines, such as SDF-1a,
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endothelial progenitor cells (EPCs) and MDSCs [11,12] which
have been shown to facilitate tumor progression in animal models
andpatients[13,14]. HSPGsthemselvescanalsoserve asligands for
adhesion molecules such as P-selectin, which can mediate tumor-
platelet and tumor-endothelial cell interactions [15] during disse-
mination of metastatic cells. Notably, HSPG-deficient tumor cells
have been reported to exhibit severely impaired ability to form
tumors in-vivo [16]. The convergence of multiple host- and tumor-
derived factors on HSPGs makes them an attractive target for
therapeutic intervention.
Using a systematic process to critically examine the structure-
function relationships for heparan sulfate mimetics, we developed
M402, a rationally engineered heparan sulfate (HS), which elicits
anti-tumor activity by effectively modulating tumor-host interac-
tions. We demonstrate that M402 is able to target and attenuate
multiple pathways important for disease progression and that in
conjunction with a cytotoxic agent is able to significantly extend
the life of disease-burdened animals. Taken together, these results
demonstrate that attenuating multiple extracellular signaling path-
ways with a heparin sulfate mimetic can have a significant effect
on tumor burden and formation and growth of metastatic loci.
Materials and Methods
Ethics Statement
All animal experiments were conducted in compliance with the
NIH Guidelines for the Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee of
Momenta Pharmaceuticals, Inc. Protocol # 01-2007.
Animals, cell lines and reagents
Mice were purchased from Charles River Laboratories (Wil-
mington, MA).
The murine B16F10 melanoma cell line was acquired from
Dr. Fidler (M.D. Anderson Cancer Center, Houston, TX). The
murine 4T1 breast cancer line was purchased from ATCC
(Manassas, VA). The 4T1-luc2-1A4 cells line [17] was acquired
from Caliper LifeSciences (Alameda, CA) and selected for high
luciferase expression and high metastatic rate by in vivo selection in
BALB/c mice. Human T cell lymphoma Jurkat and murine
leukemia WEHI-3 cells were purchased from ATCC.
Dalteparin sodium injection (10,000 IU/ml, Eisai, Inc, Ridge-
field Park, NJ), Cisplatin injection solution (Bedford Laboratories,
Bedford, OH) and Docetaxel injection solution (Sanofi Aventis
U.S., LLC, Bridgewater, NJ) were freshly diluted before each
injection.
Preparation of M402
M402 was prepared by controlled depolymerization of
unfractionated heparin in the presence of nitrous acid to yield a
low molecular weight heparin having an average molecular weight
of approximately 5500–6500 Daltons. This compound was further
subjected to sequential periodate oxidation and borohydride
reduction treatmentsand the final product was isolated and
purified by salt-methanol precipitation to yield M402.
Preparation of M-ONC 202
As described above, controlled depolymerization of unfraction-
ated heparin was carried out in the presence of nitrous acid to
yield a low molecular weight heparin with an average molecular
weight of approximately 5500–6500 Daltons. The LMWH was
converted to its pyridinium salt and subsequently N-desulfated
following a modification of the solvolytic method as reported by
Nagasawa et. al. [18] to yield M-ONC 202.
Anti-coagulant activity
Plasma samples were tested for anti-Xa activity using the Chro-
mogenix Coatest Heparin kit (Diapharma, West Chester, Ohio)
on a COAG-A-MATE MTXII instrument (Organon Teknika
Corporation, Durham, NC) according to manufacturers’ protocols.
Activated partial thromboplastin time (aPTT) was measured using
the DAPTTIN TC kit (DiaPharma Group Inc, West Chester, OH).
Surface Plasmon Resonance Assays
Surface Plasmon Resonance (SPR) assays were conducted on
a Biacore T100 instrument (GE Healthcare, Piscataway, NJ).
Neutravidin (Pierce Biotechnology, Rockford, IL) was immobilized
on a CM4 sensor chip. Biotinylated low molecular weight heparin
was captured on the sample flow cell. Growth factors including
FGF2, HGF, VEGF, and SDF-1a (4, 5, 25, and 50 nM,
respectively) were mixed with dilution series of each heparin
sample and injected over flow cells. All data was single reference
subtracted. A four parameter curve was used to fit slope versus
concentration data for the standard curve. The free concentration
of soluble factors in each test sample was calculated from the
standard curve. The KD was calculated by the following equation:
KD~ Pfree

Htotal ½ 

Pbound ½ 
where P is protein concentration in molar units and H is the
heparin concentration in mass/volume units. The reported value
is the average KD calculated at three heparin concentrations.
Inhibition of the P-selectin/PSGL1 interaction by heparin-
derived molecules was determined by an inhibition assay. A
dilution series of each heparin-derived molecule was mixed with
25 nM P-selectin (R&D systems, Minneapolis, MN). Each mixture
was flowed over the sensor surface coated with PSGL1 and the
response at equilibrium was measured. The IC50 was calculated
from equilibrium response versus concentration data by non-linear
regression in GraphPad Prism. The constant of inhibition (Ki) was
calculated from the IC50 using the Cheng-Prushoff equation.
Heparanase activity
Heparanase activity was measured using CisBio Bioassays
technology based on time-resolved fluorescence energy transfer
(TR-FRET) between europium cryptate and XL665 (allophycocya-
nin). The recombinant heparanase was pre-incubated with different
concentrations of the heparin-derived compounds for 15 min at
37uC prior to adding to biotin-cryptate labeled heparin sulfate
substrate and incubating with streptavidin-XL665 for 1 h at 37uC.
SDF-1a/ CXCR4 chemotaxis assay
Cultured Jurkat cells (at 1610
7 cells/ml, 0.1 ml) were added to
the upper chambers of the 3 mM chemotaxis plate (Corning
Incorporated, Corning, NY). Different concentrations of LMWH
were combined with 3 ng/ml SDF-1a (R&D Systems) and added
to the lower chamber of a 24 well, chemotaxis plate in triplicate
and incubated for 1 hr at 37uC with 5% CO2. Migrated cells were
transferred from lower chamber of the chemotaxis plate into flow
cytometry tubes and cell numbers quantified on a FACSCanto
(BD BioSciences, San Jose, CA) at a fixed flow rate for 30 seconds.
HUVEC spheroid sprouting assay
The assay was performed with a modified procedure as reported
by Korff et al. [19]. Spheroids were prepared by pipetting HUVEC
Heparan Sulfate Mimetic Targets Multiple Pathways
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roid aggregation, before seeding in a collagen solution in the
absence or presence of the test compound in a 24 well plate.
Different growth factors were added on top of the polymerized gel.
Plates were incubated at 37uC for 24 h and fixed by adding 4%
paraformaldehyde. Images from 10 spheroids per well/data point
were randomly taken using an inverted microscope. The EC
sprouts with branches of each spheroid were traced manually with
the digital imaging software Analysis 3.2 (Soft imaging system,
Mu ¨nster, Germany). All measured lengths were added to give the
cumulative sprout length (CSL) of this spheroid.
Flow cytometry analysis
Blood samples were collected by cardiac puncture. For flow
cytometry analysis, 100 ml blood samples were suspended in 4 ml
16RBC lyses buffer (eBiosciences, San Diego, CA), washed and
stained with a cocktail of antibodies. All antibodies were purchased
from BD Biosciences (San Diego, CA) or eBiosciences. Flow cyto-
metry analyses were performed on a FACSCanto (BD Biosciences,
San Jose, CA), and data analyzed with FlowJo (TreeStar, Palo
Alto, CA).
Murine B16F10 melanoma experimental metastasis
model
Groups of female C57BL/6 mice (n=8–13) were injected with
a single dose of saline or different heparin-derived compounds
at various concentrations subcutaneously, immediately followed
by intravenous injection of 2610
5 B16F10 cells. Animals were
monitored daily and body weight recorded weekly. On day 20
after tumor inoculation, animals were euthanized by CO2 asphy-
xiation and necropsy performed. Lungs were isolated weighed and
then fixed in buffered formalin (VWR international, West Chester,
PA). Tumor colonization to different organs was examined.
Human C170HM2 colon carcinoma experimental
metastasis model
Groups of male MF1 nude mice (n=10) were injected intra-
peritoneally with 1.5610
6 C170HM2 human colon carcinoma
cells [20]. Daily subcutaneous injection of saline or M402 at
different doses was administered staring from day 1 until the
experiment was terminated 35 days after tumor inoculation. At
necropsy, liver tumors were excised, weighed and cross-sectional
areas measured.
Murine 4T1 mammary carcinoma orthotopic model
Female BALB/c mice were injected into the 4
th mammary fat
pad with 4T1 or 4T1-Luc2-1A4 cells. Primary tumors were re-
moved by surgery. Animals were monitored closely and euthanized
when displaying signs of distress or until the experiment was
terminated on day 32.
Labeling of M402 with fluorescent dye
Fluorescent-labeled heparin was prepared by treating M402
with HiLyte Fluor
TM 750 Hydrazide (AnaSpec, Fremont, CA) in
the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC, Sigma-Aldrich Chemicals, St. Louis, MO) at room tem-
perature. The final product was isolated and purified by salt-
methanol precipitation.
Histology and immunohistology
Formalin-fixed lungs were embedded whole in paraffin and
sections prepared. The slides were stained with hematoxylin and
eosin (H&E). Tumor metastases were counted in one full section of
the lung, tumor burden was quantified by cross-sectional tumor
areas as a percentage of total lung area. Immunohistology studies
were performed with formalin-fixed primary tumors and lung
tissues. Standard colorimetric immunohistochemical methods
were used to stain paraffin sections for CD31 using a rat mono-
clonal antibody (Biocare Medical, Concord, CA) and reagents
required for the avidin-biotin peroxidase method for the detection
of the antigen-antibody complex.
Statistical analysis
The statistical significance of differential findings between
experimental groups and controls was determined by one-way
ANOVA or t-test. Log-Rank test was used for elongation of life-
span studies. Analyses were performed using GraphPad Prism
software (GraphPad Software Inc., San Diego, CA). Findings were
regarded as significant if P,0.05.
Results
Engineering of M402
Both clinical and animal model studies indicate that heparins
mediate anti-tumor activity [21,22]. However, the ability to fully
exploit the anti-tumor properties of heparin has been limited by its
anticoagulant activity. Therefore, we desired to create a heparin-
like compound with limited anticoagulant activity that still
retained binding to key factors important in tumor growth and
metastasis. Indeed, heparin-binding proteins such as VEGF,
FGF2, SDF-1a, HGF and P-selectin have been shown to mediate
angiogenesis, tumor and host cell trafficking, tumor cell mobility
and tumor cell seeding. Based on our investigation of the structure-
binding dependence of these growth factor-heparin interactions
[23], we designed a lead candidate, abbreviated M402 (Table 1).
M402 displayed much lower anticoagulant activity in vivo, as mea-
sured by plasma anti-Factor Xa activity (AUC of 56.9 min.IU/ml)
compared to animals receiving an equal dose of the low molecular
weight heparin (LMWH) dalteparin (AUC of 835.5 min.IU/ml)
(Figure 1A, left panel). LMWH heparins, such as dalteparin, are
known to have weak activity in the activated partial thromboplastin
time (aPTT) assay, which is primarily a measure of anti-Factor IIa
activity. As expected, M402 exhibited reduced aPTT activity
compared to dalteparin (Figure 1A, right panel).
We tested the binding affinities of M402, dalteparin and M-
ONC 202 (an N-desulfated LMWH displaying a similar molecular
weight profile and no significant anti-Xa activity, but lacking im-
portant structural features associated with growth-factor binding,
Figure 1A, Table 1) to VEGF, FGF2, SDF-1a, HGF and P-selectin.
Both M402 and dalteparin exhibited equivalent affinity for FGF2,
VEGF, SDF-1a and HGF (Figure 1B). In contrast, M-ONC 202,
consistent with its structural attributes, displayed a reduced binding
to all four proteins (Figure 1B). M402 was also able to block P-
selectin/PSGL interaction with a Ki similar to that of dalteparin,
while M-ONC 202 was significantly less effective in blocking the
interaction (Figure 1C). Interestingly, M402 was approximately 6-
fold more potent than dalteparin in inhibiting heparanase activity,
with an IC50 of approximately 5 mg/ml (Figure 1D). In contrast, M-
ONC 202 showed poor heparanase inhibitory activity with an IC50
of 37 mg/ml. These results clearly indicated the successful engi-
neering of M402 to possess substantially reduced anticoagulant
activity while retaining binding activity to key heparin-binding
proteins.
To determine the contribution of anticoagulation to anti-tumor
activity, M402 and dalteparin were tested in the B16F10
experimental metastasis model at equivalent doses based on anti-
Factor Xa activity. Lung weight at necropsy, 20 days after tumor
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weights of naı ¨ve animals of similar age consistently ranged within
0.1760.02 g and the weight gain of tumor-bearing lungs corre-
lated with both tumor nodule number and nodule size. M402
demonstrated superior anti-tumor activity to dalteparin at equi-
valent doses based on anti-Xa activity (Figure 1E), indicating that
the antitumor activity of M402 is independent of anticoagulant
activity.
Next, M402 was tested in a second experimental metastasis
model involving human C170HM2 colon carcinoma cells [20]
injected into the peritoneum of male MF1 nude mice. Previous
studies reported that LMWHs were unable to inhibit liver colo-
nization of i.p. inoculated colon cancer cells [24]. M402 treat-
ment, starting 1 day after C170HM2 cell inoculation, significantly
reduced the liver tumor load in a dose-dependent manner when
compared to the vehicle control group (Figure 1F). Taken
together, these data demonstrate the activity of M402 in experi-
mental models of metastases.
M402 inhibits both tumor and host cell functions in vitro
Next we examined the ability of M402 to inhibit the activity
of tumor or endothelial cells in vitro.M 4 0 2a n dM - O N C2 0 2
were tested in an SDF-1a induced chemotaxis assay, using
Jurkat tumor cells which were shown to express high levels of
CXCR4, the cognate receptor for SDF-1a.M 4 0 2i n h i b i t e d
SDF-1a-induced Jurkat cell migration, with an IC50 of
approximately 10 mg/ml, while M-ONC 202 showed greatly
reduced potency in the same assay, with an IC50 of around
500 mg/ml (Figure 2A).
M402 was also tested in a growth factor-induced HUVEC cell
spheroid sprouting assay (Figure 2B). M402 effectively inhibited
sprouting of HUVEC cells in collagen gel induced by VEGF-A
with an IC50 of 20.9 mg/ml, while the negative control M-ONC
202 had very little effect in the same assay, with an IC50 of around
500 mg/ml. Importantly, M402 also inhibited endothelial cell
sprouting induced by FGF2 (Figure 2B), HB-EGF, and deferox-
amine-induced hypoxia with IC50s of 5.6, 3.2, and 6.5 mg/ml,
respectively.
Previous studies have shown that activation and binding of
platelets to circulating tumor cells through a P-selectin-dependent
mechanism facilitates seeding of tumor cells to distal tissues
[15,25]. M402 reduced the number of tumor-platelet rosettes to
almost baseline levels when activated platelets were incubated in
vitro with PSGL-expressing WEHI tumor cells (Figure 2C). This
was also confirmed by in vivo studies in the B16F10 experimental
metastasis model (see Figure 1E and results described above), a
model shown to depend on P-selectin [15]. Taken together, these
data indicate that M402 effectively inhibited the function of SDF-
1a, VEGF, FGF2, HB-EGF, and P-selectin.
M402 alone or in combination with chemotherapeutics
demonstrates a survival benefit in the 4T1 murine
mammary carcinoma orthotopic model
Given the ability to inhibit multiple pathways, we tested the
efficacy of M402 in the orthotopic 4T1 murine mammary
carcinoma model, an aggressive model of tumor progression and
spontaneous metastasis [26]. Virtually all mice die from extensive
lung metastases following resection of the primary tumor, even
with treatment with conventional chemotherapeutic agents. M402
was tested first as monotherapy, and when delivered by sub-
cutaneously-implanted osmotic pump (40 mg/kg/day), demon-
strated a significant survival benefit when compared to the saline
control group (P,0.02 by Log-Rank test) with 10% of the animals
surviving past 160 days (Figure 3A).
We next investigated the use of M402 in combination with a
standard of care cytotoxic agent. We reasoned that targeting
microenvironmental factors with M402 would be complementary
to targeting proliferating tumor cells with a chemotherapeutic
agent. To monitor tumor progression, 4T1 cells were transfected
with the luciferase gene and selected for high luciferase expression.
4T1 cells with high metastatic potential were selected by subjecting
them to in vivo passaging [17]. Both M402 (40 mg/kg/day) and
docetaxel (10 mg/kg) monotherapy moderately attenuated meta-
static tumor progression, as indicated by whole body biolumines-
cence. M402 monotherapy showed a trend towards improved
survival, but did not reach statistical significance in this study
(p=0.10 by Log-Rank test). However, the combination of M402
and docetaxel substantially inhibited metastatic tumor growth
(Figure 3B and 3C) and significantly improved overall survival
compared to the saline control and docetaxel monotherapy
(P,0.001, and P,0.05, respectively, Log-Rank test; Figure 3D).
Notably, mice treated with M402 at 40 mg/kg/day for up to 90
days showed no significant bleeding or gross side effects such as
weight loss or lethargy.
M402 accumulates and persists in 4T1 primary tumors
M402 administered by osmotic pump at 20 mg/kg/day
displayed antitumor efficacy and was shown to deliver a steady
state plasma trough level of approximately 20 mg/ml. This trough
level maintains M402 concentrations above the IC50 calculated for
M402 inhibiting VEGF, FGF2, HB-EGF, heparanase and SDF-
1a activity (Figure 2A and 2B). Daily subcutaneous injections of
20 mg/kg M402 showed a similar degree of efficacy in the 4T1
orthotopic model as that observed with M402 administered by
osmotic pump, despite the fact that M402 has a relatively short
plasma half-life of approximately 2 h (Figure 1A).
We further investigated whether M402 selectively accumulates
in tumor tissue, using M402 labeled with HiLyte Fluor
TM 750 dye.
In normal mice, fluorescent signal was observed in the liver and
Table 1. Physiochemical characteristics of M402, M-ONC 202 and Dalteparin.
Characteristic M402 M-ONC 202 Dalteparin
Chemical characteristic Glycol split LMWH N-desulfated LMWH Commercial LMWH
Anti Xa (IU/mg) ,10 0 160
Anti IIa (IU/mg) ,40 6 0
Average Molecular Weight (Da) 6000 6300 6200
Polydispersity 1.5 1.4 1.3
doi:10.1371/journal.pone.0021106.t001
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rapid clearance of LMWH through the kidney and liver. In tumor-
bearing animals, M402-associated fluorescent signals also co-
localized with 4T1 cells implanted in the first mammary fat pad
(Figure 4A, upper panels). Importantly, the fluorescent signal in
the primary tumor area persisted up to 8 days after a single
injection (Figure 4B). This observation was confirmed by ex-vivo
imaging of isolated tumors as well as by biodistribution studies
performed with
3H-labeled M402. In contrast, in tumor-bearing
mice injected with free dye, the fluorescent signal accumulated
mostly in the bladder within the first 4 h, and was not detectable
24 h after injection (Figure 4A, lower panels, Figure 4B). These
results indicate that M402 accumulates and persists in tumor
tissue.
M402 reduces microvessel density in primary tumors
Based on the observed accumulation of M402 in the primary
tumor, we next performed immunohistological analysis of the
surgically resected primary tumors. At the time of tumor resection,
which was only 4 days after the start of M402 treatment, there was
no significant difference in tumor weight between the groups.
However, even at this early time point, immunohistological ana-
lysis demonstrated significantly reduced CD31 staining in primary
tumors from animals treated with M402 (Figure 4C), indicating
reduced microvessel density in the tumor.
M402 in combination with cisplatin inhibits tumor
progression and angiogenesis at the metastatic site and
normalizes circulating levels of myeloid derived
suppressor cells (MDSCs)
M402 was tested in combination with another standard of
care chemotherapeutic, cisplatin, in the orthotopic 4T1 murine
mammary carcinoma model. M402 and cisplatin therapy was
initiated 5 days after tumor inoculation, around the time of onset
of tumor dissemination in this model. Quantification of metastasis
by lung weight (Figure 5A) or by histological evaluation (Figure 5B)
demonstrated that the anti-tumor activity of M402 in combination
with cisplatin was greater than that observed in the saline control,
or in the cisplatin monotherapy group. CD31 immunohistology
analysis was also performed on the lung tumors. Lung tumors from
the cisplatin and M402 combination therapy group displayed
significantly lower tumor microvessel density when compared to
saline or cisplatin monotherapy groups (P,0.0001 and P,0.01,
respectively; One-way ANOVA with Bonferroni’s multiple com-
parison test; Figure 5C), suggesting the combination of cisplatin
and M402 may also inhibit tumor angiogenesis at the metastatic
tumor site and contribute towards reducing overall metastatic
tumor load.
Figure 1. M402 displays low anticoagulation activity while
retaining activity against key HSPG-binding proteins. (A) Left
panel, anti-factor Xa activity: BALB/c mice were injected subcutaneously
with 10 mg/kg dalteparin, M402 or M-ONC 202. Plasma was collected at
different time points and analyzed for anti-Factor Xa activity
(Mean6SD). Experiments were performed three times with similar
results. Right panel, aPTT measured in normal human plasma. (B) The
binding affinity (Mean6SD) of M402, M-ONC 202 and dalteparin to
different heparin binding proteins was determined by Surface Plasmon
Resonance (SPR) with a competitive inhibition assay on a Biacore T100
instrument. Different heparin-derived compounds were captured on
the sensor chip with a fixed amount of growth factors including FGF2,
HGF, VEGF, and SDF-1a (4, 5, 25, and 50 nM, respectively) mixed with
dilution series of each heparin-derived compound flow through. The
IC50 (mg/mL) was calculated for each interaction. (C) Inhibition of the P-
selectin/PSGL1 interaction (Mean6SD) by heparin-derived molecules
was determined by an inhibition assay. A dilution series of each
heparin-derived compound was mixed with 25 nM P-selectin and
flowed over the sensor surface coated with PSGL1 and the response at
equilibrium was measured and the Ki was calculated. (D) Heparanase
activity (Mean6SD). Heparanase activity was measured using Cisbio
Bioassays technology based on TR-FRET. (E) Murine melanoma B16F10
experimental metastasis model. Groups (n=12–13) of female mice were
treated with saline or different heparin-derived compounds prior to iv
inoculation of 2610
5 B16F10 cells. Tumor colonization to the lung was
quantified by lung weight (Mean6SEM.) on day 20. Statistics were
performed with One-way ANOVA using Bonferroni’s multiple compar-
ison test. (F) Human C170HM2 colon carcinoma experimental metas-
tasis model. Groups of male MF1 nude mice (n=10) were injected
intraperitoneally with 1.5610
6 C170HM2 human colon carcinoma cells.
Daily subcutaneous injection of saline or M402 at different doses
started 1 day later until the experiment was terminated 35 days after
tumor inoculation. At necropsy, liver tumors were excised, weighed
(Mean6SD, left panel) and cross-sectional areas (Mean6SD, right panel)
measured.
doi:10.1371/journal.pone.0021106.g001
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+GR-1
+ MDSCs has been shown to
correlate with tumor progression in animal models and patients
[14]. MDSCs have been implicated as angiogenic switch triggers
[27] and in contributing to tumor resistance to anti-VEGF treat-
ment [2]. M402 treatment, either as monotherapy or in combi-
nation with cisplatin, reduced metastatic 4T1 tumor-induced
expansion of MDSC (Figure 5D). The reduction of circulating
MDSCs in the M402 monotherapy group was similar to that
observed in the combination therapy group (Figure 5D), despite
the fact that the tumor load in the M402 monotherapy group was
substantially greater than that of the combination therapy group
(Figure 5A and B). These data suggest that M402 may directly
affect MDSC expansion.
Discussion
Cancer is a complex disease involving changes to multiple
pathways [28,29] and microenvironments. Wels et al have
proposed a complex interplay between the primary tumor, sites
of metastases, and the bone marrow (illustrated in Figure 6) that is
mediated by soluble factors [1]. In this model, tumor cells secrete
soluble factors that can modify the microenvironment of distal
tissues (e.g. sites of metastases) or induce mobilization of bone
marrow-derived cells that are recruited to the primary tumor or to
metastatic lesions [1]. We believe that heparan sulfate proteogly-
cans could play a central role in orchestrating these signals by
binding and presenting growth factors and chemokines that are
involved in remodeling microenvironments and recruiting distal
cells. Indeed, many of the key soluble factors implicated in defining
tumor-associated niches, such as VEGF, PlGF, SDF-1a, S100A8,
S100A9, SAA3, TNF-a, and TGF-b [6] are HSPG-binding
proteins. M402, a novel HSPG mimetic, was designed to inhibit
multiple pathways involved in tumor progression and metastasis.
The anti-tumor effects of heparin or related molecules are well-
documented [15,24,30,31]. A number of retrospective and pro-
spective clinical studies have indicated that heparin therapy may
prolong survival of cancer patients across a variety of solid tumor
types [32,33]. Several heparin-derived molecules and synthetic
carbohydrate compounds are undergoing preclinical and clinical
development [34–36]. Despite repeated efforts, definitive data
supporting anti-tumor activity of heparins in randomized clinical
trials has been lacking [37] possibly because such studies have
been constrained by the dose limiting anti-coagulant properties of
heparin. Non-anticoagulant heparin-related molecules have been
generated by various methods, such as desulfation of the 2O- and
3O-positions or N-desulfation followed by glycol-splitting [22,38].
Recently, two novel heparan sulfate mimetics, PG545 and
SST0001, have been described in the literature as potential anti-
angiogenic/anti-metastatic agents [39,40]. PG545 is a synthetic,
fully-sulfated tetrasaccharide functionalized with a cholestanyl
aglycon that shows potent inhibition of heparanase with low
anticoagulant properties. PG545 exhibits a long plasma half-life
and shows activity in multiple models of cancer [40]. On the other
hand, SST0001 is an N-acetylated, glycol-split high molecular
weight heparin that also exhibits low anticoagulant activity,
selectively inhibits heparanase and has shown activity in an in
vivo model of multiple myeloma [39]. However, N-acetylation of
heparin sequences has been shown to also reduce binding affinity
against many heparin-binding proteins, such as VEGF, FGF2, and
SDF-1a [41]. These activities may be important for the anti-tumor
activity of heparin. M402 has been specifically engineered to
substantially reduce anticoagulant activity while retaining or
improving its heparan sulfate-like binding properties to multiple
targets involved in tumor progression and metastasis.
It is difficult to define a single ‘smoking gun’ with respect to
M402’s mechanism of action. This is likely due to the fact that
M402 affects multiple pathways that regulate tumor cell inter-
actions with its microenvironment. Studies investigating the me-
chanism of action of heparin in cancer have primarily focused
on a few pathways. Folkman was the first to describe the anti-
angiogenic properties of heparin, which is mediated by multiple
Figure 2. M402 inhibits tumor and host cell functions in vitro.
(A) The SDF-1a-mediated migration assay was performed as described
in Materials and Methods. Results are presented as % inhibition of
migrated cell numbers. (B) M402 inhibited VEGF and FGF2 induced
HUVEC sprouting. Upper panels: Representative images taken 24 hrs
after incubation with VEGF-A in the presence and absence of M402 or
M-ONC 202 at 30 mg/ml. Lower panels: Cumulative sprout length (CSL,
Mean6SD) at different doses of M402 or M-ONC 202 in the presence of
VEGF (left panel) or FGF2 (right panel). (C) M402 inhibited tumor
platelet rosettes. Activated platelets were incubated for 30 min at RT
with murine WEHI-3 leukemia cells (CD45
+) pre-mixed with M402
(500 mg/ml). Platelets were stained with anti-CD41-PE and WEHI cells
with anti-CD45-FITC antibodies. Platelet-WEHI-3 aggregates were
imaged by immunofluorescence microscopy (upper panels) or quanti-
tated by flow cytometry (lower panels).
doi:10.1371/journal.pone.0021106.g002
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described the inhibitory effects of heparin on P-selectin-mediated
cloaking of tumors cells by platelets, which promote tumor
dissemination [15,43]. Vlodavsky and colleagues have published
extensively on the role of heparanase, a heparin sulfate-cleaving
enzyme, in tumor progression [44]. M402 inhibits these pathways
and others with similar or increased potency with respect to low
molecular weight heparin, but with greatly reduced anti-Factor Xa
activity.
The current armamentarium of targeted therapies aimed at
specific factors, such as VEGF, have shown great promise in a
variety of solid tumors. However the beneficial activity of anti-
VEGF therapies, such as bevacizumab, is generally short lived.
Tumors adapt by exploiting alternative angiogenic factors and
Figure 3. M402 monotherapy or in combination with docetaxel shows survival benefits in the orthotopic murine mammary
carcinoma 4T1 model. ( A )G r o u p so ff e m a l eB A L B / cm i c e( n=2 0 )w e re inoculated orthotopically with 1610
5 4T1 cells in the 4th mammary fat
pad on day 0. M402 treatment delivered by sc implanted osmotic pumps at 40 mg/kg/day started on day 1. Primary tumors were removed on
day 10. Survival of the M402 treated group was significantly longer than that of the saline control group (P,0.02 by Log-Rank test). (B–D)
Groups of female BALB/c mice (n=16) were inoculated orthotopically with 5610
4 4T1-luc2-1A4 cells in the 4th mammary fat pad on day 0.
M402 treatment delivered by sc implanted osmotic pumps at 40 mg/kg/day started on day 1. Primary tumors were removed on day 10 by
surgery. Weekly ip injection of saline or docetaxel (10 mg/kg) started on day 14. After primary tumor resection, animals were monitored twice
weekly with bioluminescent imaging. (B) Whole body bioluminescence (Mean6SEM) quantified as photons/second over time. (C)
Bioluminescence imaging of all the experimental animals on day 29. (D) Kaplan-Meier survival curve. Survival of the M402 and docetaxel
combination group was significantly longer than that of the saline control and the docetaxel monotherapy group (P,0.0001 and P,0.05,
respectively, by Log-Rank test).
doi:10.1371/journal.pone.0021106.g003
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ting in resistance to cancer therapies and often the emergence
of tumor cells with a more aggressive phenotype [3,4,45]. It is
notable that M402 inhibits endothelial sprouting in response to
FGF2 and HB-EGF as well as VEGF. In addition, M402-treated
animals showed reduced numbers of circulating myeloid derived
suppressor cells (MDSCs or CD11b
+GR-1
+ immature myeloid
cells). MDSCs have been associated with tumor progression and
angiogenesis [14], and may contribute to the development of
tumor resistance to anti-VEGF treatment [2].The multi-targeted
nature of M402 suggests the possibility that it may confer pro-
tection against the development of resistance to VEGF-specific
therapies.
There has been an increased effort in identifying combinations
of targeted drugs that can be used together in cancer treatments.
However, combining potent single-targeted drugs is often limited
by their safety profile, and can result in unexpected adverse
activity [5]. Moreover the expense of combining targeted therapies
has put significant pressure on the healthcare system. Targeting
HSPGs is an attractive approach to targeting multiple pathways
because of the versatility of HSPG functions and their importance
in facilitating tumor progression [30]. Potent antibody- or small
molecule-based therapies represent a digital or ‘on-off’ approach
to inhibiting a specific pathway. Because of its relatively low
affinity in binding to different key proteins, M402 represents an
analog approach to attenuate, rather than completely shutting off,
multiple pathways. This broad based attenuation of multiple
pathways may confer a safety advantage over combination of
current drugs that completely shut down critical pathways.
Studies interrogating heparin antitumor activity in vivo have
been primarily restricted to experimental metastasis models
wherein tumor cells are injected i.v. concurrently with a single
injection of heparin. Varki and colleagues have demonstrated that
heparin inhibition of P-selectin accounts for a major portion
of heparin’s activity in experimental models of metastasis by
inhibiting platelet-tumor cell binding, which is thought to protect
tumor cells in circulation and facilitate tumor cell binding to
vascular endothelial cells [15,46]. We have shown that M402 also
inhibits experimental metastasis in two models, the B16F10 i.v.
model and the human C170HM2 colon carcinoma model. The
fact that a single dose of heparin or M402, administered con-
currently with B16F10 cells, inhibits lung colonization indicates
that this model primarily reflects tumor seeding. The anticoagu-
lant properties of heparin may have constrained the ability to
interrogate the effects of chronic dosing of heparin on tumor
progression in spontaneous models of metastases.
To investigate the effects of M402 on metastatic processes
beyond tumor dissemination, we tested M402 in a highly aggre-
ssive model of spontaneous metastasis utilizing orthotopically im-
planted syngeneic 4T1 mammary carcinoma cells. This model
recapitulates multiple aspects of tumor dissemination, progression
and clinical outcome similar to that of Stage IV human breast
Figure 4. M402 targets primary tumors. Fluo-M402 biodistribution in 4T1 tumor bearing mice. Female Balb/c mice were implanted
orthotopically into the first mammary fat pad at a concentration of 1610
5 4T1 cells on Day 0. Mice were injected on Day 3 with a single subcutaneous
dose of either 10 mg/kg fluorescently-labeled M402 or free dye of approximately the same intensity in saline. (A) Mice were imaged in the ventral
view at various time points after injection with Fluo-M402 (upper panels) or free dye (lower panels). White circles indicate primary tumors, and yellow
boxes highlight signals from the liver regions. (B) Quantification of fluorescent signals (Mean6SEM) at the primary tumor site at different times after
Fluo-M402 or free dye injection. (C) CD31 immunohistology. Groups of female BALB/c mice (n=16) were inoculated orthotopically with 8610
4 4T1
cells in the 4th mammary fat pad on day 0. Saline or M402 (20 mg/kg/day) treatment delivered by s.c. implanted osmotic pumps started on day 5.
Primary tumors were removed on day 9 by surgery and the tumor weights were recorded. There was no significant difference in primary tumor
weight between the groups 4 days after the start of the treatments. Primary tumors were fixed in buffered-formalin, embedded in paraffin and
stained for CD31 by immunohistochemistry. Representative CD31-staining is presented in the left panel where the brownish staining (arrows)
indicate CD31
+ vessels. Quantification of microvessel density as numbers of CD31
+ vessels/406field (Mean6SEM) is displayed on the right. *, P,0.05
(t-test) when compared with saline control group.
doi:10.1371/journal.pone.0021106.g004
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following aspects: 1) inoculation of a single 4T1 tumor cell has the
potential to develop into a tumor [17]; 2) the doubling time of the
tumor cells in vivo is approximately 24 hours as measured by
bioluminescent imaging, which means that a 75% reduction in
tumor load would translate into an extension of median survival by
only 2 days; and 3) standard chemotherapeutic agents show weak
activity in this model. We demonstrate that M402, in combination
with chemotherapeutic agents, significantly decreased metastatic
tumor burden and increased survival compared to mice treated
with chemotherapy alone. The effect of M402 on tumor pro-
gression beyond dissemination is reflected in reduced microvessel
density, in both the primary tumor and in metastatic lesions.
These results are consistent with our observation that M402
selectively accumulates in tumor tissue. Recent studies have
also demonstrated the superior efficacy of M402 in combination
Figure 5. M402 inhibits tumor progression and angiogenesis at the metastastic site and normalized circulating MDSCs in vivo. (A)
M402 combined with cisplatin inhibited lung metastasis of orthotopically inoculated 4T1 tumors. The experimental set up is described in the legand
of Figure 4C. The experiment was terminated on day 32, lung tissues were isolated and lung weight (Mean6SEM) quantified (A). Fixed lungs were
embedded in paraffin and % tumor (as % of total section areas, Mean6SEM) quantified under the microscope on H&E stained slides (B). Left panels
show representative pictures of H&E staining where the solid darker purple stained areas (indicated by solid yellow arrow heads) represent metastatic
lung tumors and the lighter-stained porous areas (indicated by white open arrows) are the normal lung tissues. Tumor areas were quantified as
described in Materials and Methods, and the results are displayed in the right panel. *, P,0.05 compared to saline control, Cisplatin, and M402
monotherapy groups; one-way ANOVA. (C) Lung tissues were also stained with CD31 immunohistology. Representative images from saline and
combination therapy treated lung tumors are presented in the left panel where the CD31
+ vessels are indicated by the arrows. CD31
+ vessels
(Mean6SEM) were quantified in the tumor areas and results displayed in the right panel. Statistics were performed with One-way ANOVA using
Bonferroni’s multiple comparison test. (D) Blood samples obtained by cardiac puncture were analyzed by flow cytometry. Left panel: representative
CD11b and GR-1 staining of blood CD45
+ cells of naı ¨ve or 4T1-tumor bearing mice. Right panel: quantification of MDSCs as % of total cells
(Mean6SEM) in different treatment groups. *, P,0.05; **, P,0.01 compared to saline control group (one-way ANOVA).
doi:10.1371/journal.pone.0021106.g005
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(Kras
LSL-G12D/+; p53
LSL-R172H/Flox) of pancreatic cancer (AACR
Annual Meeting 2010 Proceedings). These studies indicate that
M402 affects tumor progression beyond tumor dissemination.
Moreover these studies show that activity of M402, which targets
multiple host microenvironmental factors, can be complementary
to the direct antitumor activity of conventional chemotherapeutics
agents.
In summary, our data demonstrate that targeting HSPG biology
represents a potential novel strategy to treat multiple facets of
cancer. Heparin, from which M402 is derived, has been used
clinically for decades with an acceptable and well understood
risk-benefit profile. M402 has been specifically engineered to sub-
stantially reduce anticoagulant activity while retaining or improv-
ing its other heparan sulfate-like binding properties. Here we
demonstrated that M402 successfully interfered with various path-
ways essential for tumor progression, as well as targeted different
tumor compartments. The efficacy, safety, and multimodal activity
of M402 will need to be established in human clinical trials.
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